Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advantage Novo As Victoza Gets CV Benefit Okay in Europe

Executive Summary

Victoza is the only drug in the GLP-1 class in Europe to have a label that includes the prevention of CV events (and only the second antidiabetic after Boehringer Ingelheim/Lilly’s SGLT2 inhibitor Jardiance) which will help slow down market share loss to Lilly's Trulicity.

Advertisement

Related Content

Novo Nordisk Says More To Victoza Outcomes Benefit Than A GLP-1 Class Effect
Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market
Semaglutide Should Transform Novo Nordisk's Prospects, CSO Says
Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza
EASD 2016: Semaglutide Steals The Show With Impressive Cardiovascular Outcomes Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel